Correct Answer: B. Beta lactam antibiotics
Mycoplasma species lack a cell wall entirely—they possess only a plasma membrane bounded by a lipid bilayer. Beta-lactam antibiotics (penicillins, cephalosporins, carbapenems) exert their bactericidal effect by inhibiting peptidoglycan cross-linking and disrupting cell wall synthesis. Since Mycoplasma has no cell wall and no peptidoglycan, beta-lactams have no target to attack, rendering them completely ineffective. This is the defining structural feature that explains Mycoplasma's inherent resistance to the entire beta-lactam class. In Indian clinical practice, when treating suspected Mycoplasma pneumoniae (a common cause of atypical pneumonia in children and young adults), beta-lactams are avoided entirely, and macrolides or tetracyclines are the drugs of choice. This is a high-yield discriminator in microbiology examinations.
Why the other options are wrong
A. Macrolides — Macrolides (azithromycin, erythromycin) are highly effective against Mycoplasma. They inhibit bacterial protein synthesis by binding to the 50S ribosome, a mechanism that works regardless of cell wall presence. Macrolides are the first-line agents for Mycoplasma pneumoniae in India, especially in pediatric atypical pneumonia. This is a classic trap—students may confuse Mycoplasma resistance patterns. C. Tetracycline — Tetracyclines (doxycycline, tetracycline) are also effective against Mycoplasma by inhibiting 30S ribosomal protein synthesis. They are an alternative first-line agent in adults with Mycoplasma infection. The NBE trap here is pairing Mycoplasma with a list of antibiotics and expecting students to recognize that only beta-lactams are ineffective. D. Fluoroquinolones — Fluoroquinolones (levofloxacin, moxifloxacin) inhibit bacterial DNA gyrase and topoisomerase IV, mechanisms independent of cell wall structure. They are effective against Mycoplasma and are used as alternative agents in resistant cases or in patients with macrolide allergy. Their mechanism bypasses the cell wall entirely.
High-Yield Facts
- Mycoplasma lacks a cell wall—only plasma membrane; this is the structural basis for beta-lactam resistance.
- Beta-lactams target peptidoglycan; without a cell wall, they have no site of action in Mycoplasma.
- Macrolides and tetracyclines are first-line agents for Mycoplasma pneumoniae in India (pediatric atypical pneumonia).
- Fluoroquinolones are effective alternatives when macrolide resistance emerges.
- Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP) in children and young adults in India; always suspect in atypical presentation.
Mnemonics
No Wall = No Beta-Lactam Mycoplasma has No Cell Wall → No Peptidoglycan → No Beta-Lactam Target. All three are linked; if you remember the first, the resistance pattern follows logically. MAFT for Mycoplasma Macrolides, Azithromycin, Fluoroquinolones, Tetracyclines work against Mycoplasma. Beta-lactams do Bounce off (are ineffective).
NBE Trap
NBE pairs Mycoplasma with a mixed antibiotic list to test whether students know the structural basis of resistance (lack of cell wall) rather than just memorizing drug names. Students who confuse Mycoplasma with typical bacteria may incorrectly select macrolides or tetracyclines, not recognizing that beta-lactams are the unique exception.
Clinical Pearl
In Indian pediatric practice, a child presenting with persistent cough and atypical pneumonia on chest X-ray should raise suspicion for Mycoplasma pneumoniae. Empiric beta-lactam monotherapy will fail; macrolide (azithromycin) is the standard choice. This distinction between atypical and typical bacterial pneumonia is critical for clinical decision-making.
_Reference: Jawetz, Melnick & Adelberg's Medical Microbiology (Chapter on Mycoplasma); Harrison's Principles of Internal Medicine (Chapter 297, Atypical Pneumonias)_